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Introducing small DNA molecules (Dbait) impairs the repair of damaged chromosomes and provides a new method for enhancing
the efficiency of radiotherapy in radio-resistant tumors. The radiosensitizing activity is dependent upon the efficient delivery of
Dbait molecules into the tumor cells. Different strategies have been compared, to improve this key step. We developed a pipeline
of assays to select the most efficient nanoparticles and administration protocols before preclinical assays: (i) molecular analyses
of complexes formed with Dbait molecules, (ii) cellular tests for Dbait uptake and activity, (iii) live zebrafish embryo confocal
microscopy monitoring for in vivo distribution and biological activity of the nanoparticles and (iv) tumor growth and survival
measurement on mice with xenografted tumors. Two classes of nanoparticles were compared, polycationic polymers with linear or
branched polyethylenimine (PEI) and covalently attached cholesterol (coDbait). The most efficient Dbait transfection was observed
with linear PEI complexes, in vitro and in vivo. Doses of coDbait ten-fold higher than PEI/Dbait nanoparticles, and pretreatment
with chloroquine, were required to obtain the same antitumoral effect on xenografted melanoma. However, with a 22-fold lower
‘efficacy dose/toxicity dose’ ratio as compared with Dbait/PEI, coDbait was selected for clinical trials.
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Introduction
Increased understanding of the molecular pathological
mechanisms of cancer, the advent of novel molecular
tools such as synthetic small interfering RNA or plasmid
DNA-based vectors and technology for their in vivo
delivery, have provided an encouraging perspective for
the use of nucleic acid-based cancer molecular therapies.
1
The efficiency and cytotoxicity of synthetic DNA delivery
systems must be further addressed to optimize nucleic
acid-based therapies. We recently demonstrated that
small interfering DNA molecules (siDNA) can be used
to trick the cell, by triggering a false DNA damage signal
that results in inhibition of DNA repair.
2,3 siDNA
mimicking DNA double-strand breaks (called Dbait)
were successfully used to sensitize tumors to irradiation.
Dbait are 32-bp long double-stranded DNA molecules
protected from exonucleases and helicases by substitu-
tion, at one end, of the 30- and 50-terminal nucleotide
residues, with phosphorothioate nucleotides and, at the
other end, by tethering the two strands with a hexa-
ethylene glycol loop.
3 Dbait administration before radio-
therapy enables control of tumor growth and, in some
cases, a cure. Dbait acts within the cell in a strictly dose-
dependent manner and, therefore, its efficient intracellular
delivery is pivotal for controlling disease.
Naked DNA does not efficiently enter the cells. To
facilitate its delivery, non-viral methods using a combina-
tion of synthetic polymers and nucleic acids to form
particles, called lipoplexes or polyplexes, have been
developed and optimized for use with large DNA in
cultured cells. It is unclear how these vectors will be
effective for small DNA and clinical applications.
Identifying and overcoming each hurdle along the DNA
entry pathways can improve DNA delivery to the nucleus
and hence, improve the overall transfection efficiency.
There are three major barriers to DNA delivery: (i) low
uptake across the plasma membrane, (ii) inadequate
release of DNA molecules with limited stability and (iii)
lack of nuclear targeting. In addition to these ‘cellular
barriers’, ‘tissue and systemic barriers’ also exist, which
include degradation, opsonization of particles by charged
serum components, rapid clearing and accumulation in
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www.nature.com/cgtnon-target tissues. In this study, we established a pipeline
of assays from analyses of physicochemical and stabil-
ity properties of complexes, imaging of cellular uptake
and tissue distribution in animals, to activity assays in
adapted cell culture and in vivo models. A multi-system
approach is necessary to successfully complete the
characterization and selection of a vector for in vivo
DNA delivery. Cell cultures have been used for vector
selection, based on activity assays, zebrafish early
embryos for quasi-instantaneous and live imaging of
cellular uptake of Dbait nanoparticles and mice for
in vivo imaging of Dbait distribution in healthy or
tumoral tissue and therapeutic efficacy assays. Integrating
these assays provides a powerful tool for selection of
the most efficient delivery system for biomolecules to
optimize pre-clinical assays.
Materials and methods
Dbait and particles formation
Dbait and coDbait molecules were obtained by auto-
mated solid-phase oligonucleotide synthesis from Euro-
gentec (Seraing, Belgium) as previously described.
2 They
were purified by denaturing reversed-phase high-perfor-
mance liquid chromatography and/or high-performance
liquid chromatography–ion exchange. Sequence in Dbait
and coDbait is: 50-GCTGTGCCCACAACCCAGCAAA
CAAGCCTAGA-(H)-TCTAGGCTTGTTTGCTGGGT
TGTGGGCACAGC-30, where H is a hexaethylene-glycol
linker. Sequence of the inactive siDNA are: 50ACGCAC
GG-(H)-CCGTGCGT-30 for the 8H and 50-AGATCGC
CAACACCGAACAAACGACCGTGCGT-(H)-AGAT
CCGAACAAACGACCCAACACCCGTGCGT-30 for
the 64ss. Some Dbait derivatives were labeled with the
fluorophores Cy3 (lexcitation¼540nm; lemission¼560nm)
or Cy5.5 (lexcitation¼650nm; lemission¼670nm). Linear
polyethylenimine (PEI) (11 and 22kDa) were obtained
from Polyplus-Transfection (Illkirch, France) and pro-
vided as a ready-to-use solution of 300mM nitrogen
concentration. Branched bPEI25kd was purchased from
Sigma-Aldrich (Saint Quentin, France). Lutrol was
purchased from In Cell Art (Nantes, France). Dbait,
coDBait and PEI solutions (stock PEI) were diluted in
10% sucrose or 150mM NaCl (for in vivo and in vitro
transfection experiments, respectively) to obtain various
ratios of vector/Dbait. The ratio of PEI/Dbait (or ratio
N/P) was determined according to the number of amine
nitrogen for PEI and phosphate for Dbait. Typically, for
300ml of complexes at 0.6mgml
 1 and N/P of 6, Dbait
(180mg, 0.54mmol of phosphate) and the desired amount
of polymer solution (11.4ml of PEI stock solution
contains 0.3mmol of amine nitrogen) were diluted into a
volume of 150ml each. Superfect/Dbait particles were
prepared according to manufacturer’s instructions
(Qiagen, Courtaboeuf, France) in a ratio of 10ml Super-
fect per mg of DNA. The vector/Dbait complexes were
analyzed by agarose gel electrophoresis method. The
samples (18ml) were mixed with bromophenol blue
dye (1ml) and electrophoresed on 1.5% agarose gels in
Tris-acetate-ethylene diamine tetraacetic acid buffer 1 
(40mM Tris-acetate, pH 8.3, 1mM ethylene diamine
tetraacetic acid) at 100V for 30min. The gel was stained
with ethidium bromide and the bands visualized under
UV light to detect uncomplexed Dbait.
Cell culture, Dbait molecules and transfection
Studies on cells in culture were performed using the
SV40-transformed fibroblasts MRC-5. Cells were grown
at 371C in monolayer cultures in complete Dulbecco’s
modified Eagle medium (DMEM) (Gibco, Cergy Pontoise,
France) with 10% fetal calf serum and antibiotics (100mgml
 1
streptomycin and 100mgml
 1 penicillin), under conditions
of 100% humidity, 95% air and 5% CO2. Unless other-
wise specified, transfections were performed in 1.2ml
DMEM medium without serum in 60mm diameter
plates. Transfection with jetPEI (Polyplus-transfection)
was performed at an N/P ratio of 6, according to the
manufacturer’s instructions. Briefly, Dbait molecules
were diluted in 150mM NaCl and gently mixed with an
equal volume of PEI in 150mM NaCl, and added to
DMEM medium without serum. CoDbait was directly
added to DMEM medium without serum. Transfection of
Dbait molecules was performed with Superfect reagent
in 1.2ml DMEM medium without serum (in 60mm
diameter plates) for 5h. For electroporation, 1.2 10
6
cells were transfected with 2mg Dbait, using the Gene
Pulser II (Bio-Rad, Marnes-la-Coquette, France). At the
end of the 5-h transfection (time zero), medium was
replaced by complete medium and cells were grown for
the indicated amount of time before analysis. Chloro-
quine (50mM) was added 30min before transfection.
DNA-dependent protein kinase (DNA-PK) activity assay
DNA-PK activity was monitored using the kit Signa-
TECT DNA-dependent Protein Kinase Assay System
(Promega, Madison, WI). The biotinylated substrate,
50 units of DNA-Dependent Protein Kinase (Promega)
and 0.25mg (500nM) Dbait molecules were incubated
for 5min at 301C with (g-
32P)ATP, according to the
manufacturer’s instructions. The biotinylated substrate
was captured on a streptavidin membrane, washed and
counted in a scintillation counter. Percentage of phos-
phorylation was calculated by dividing the bound radio-
activity by the total count of (g-
32P)ATP per sample.
Flow cytometry
Cells were transfected with different complexes with
Dbait-cy3 for 5h and directly analyzed or left to grow
for 24h. For immunofluorescence detection by flow
cytometry, the cells were fixed overnight in cold 100%
ethanol before immunodetection. Cells were perme-
abilized in 0.2% Triton X-100 for 30min, blocked with
2% bovine serum albumin, incubated for 2h on ice with
mouse monoclonal antibodies anti g-H2AX (Upstate
Biotechnology, Temecula, CA) and revealed with second-
ary antibodies conjugated with Alexa-488 (Molecular
Probes, Eugene, OR) for 30min at room temperature.
Cells were analyzed using a FACScalibur flow cytometer
(BD Biosciences, Franklin Lakes, NJ), and data was
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and the free WinMDI 2.8 (Scripps Research Institute,
La Jolla, CA) software. Note that permeabilization
treatment used for immunostaining removed most of the
Dbait, impairing accurate Dbait detection and immuno-
fluorescence detection on the same sample.
Zebrafish husbandry, embryo collection and treatment
Zebrafish eggs were obtained from natural spawning
of wild-type or transgenic (bactin:egfp-ras) fish lines.
A Narishige (MN 153) micromanipulator (East Meadow,
NY) fixed on a dissecting scope with epifluorescence
illumination (Leica MZ16F, Mannhein, Germany) and an
air injector (Eppendorf FemtoJet, Le Pecq, France) were
used to perform Dbait injection at cell stage 1K. Glass
capillaries (Harvard Apparatus GC100-10, Les Ulis,
France) were pulled with a KopF vertical pipette puller
(KopF 720, Tujunga, CA) to make injection needles. Two
to five nanoliters of Dbait solution were injected at the
animal pole of embryos in cell cycle ten and immediately
processed by confocal laser scanning microscopy imaging
(upright Leica SP2) with  40/0.8 NA water dipping lens
objective. Imaging was performed using simultaneous
480nm (enhanced green fluorescent protein) and 561nm
(cy3) excitation. Embryos were grown at 28.51C for a
further 24h post-infection. One-day-old larvae were
observed under the dissecting microscope and pheno-
types categorized as described in Figure 4. Chloroquine
treatment before injection consisted of a 2-h incuba-
tion in embryo medium
4 with 50mM chloroquine (CQ).
Dbait (coDbait)-cy3 of 50mM was injected either alone
or in combination with PEI25K (ratio N/P¼9), PEI22K
(ratio N/P¼6), PEI11K (ratio N/P¼6), Superfect
(10ml1
 1mg
 1 Dbait).
Dbait and Irradiation treatments in mice
SK28 or U87G xenograft tumors were obtained by
injecting 10
6 tumor cells into the flank of adult female
nude mice (Charles River strain; L’arbresle, France). The
animals were housed in the laboratory for at least 1 week
before commencing experiments. There were five to six
animals per cage, under controlled conditions of light and
dark cycles (12h:12h), relative humidity (55%) and
temperature (211C). Food and tap water were available
ad libitum. After approximately 12 days, when the
subcutaneous tumors measured 150–200mm
3, the mice
were separated into homogeneous groups of at most 12
each, to receive different treatments. Irradiation was
performed in a
137Cs unit (0.5Gymin
 1) with a shield
designed to protect about two-thirds of the animal’s body.
Doses were controlled by thermoluminescence dosimetry.
A total dose of 30Gy were delivered in six sessions at
intervals of three sessions of 5Gy per week for a period of
2 weeks. Dbait and coDbait molecules were prepared in
100ml of 10% sucrose. The Dbait mixtures were
incubated for 15min at room temperature before injec-
tion. Injections of the indicated amount of formulated
Dbait were performed 5h before each radiotherapy
session. Mock-treated animals were injected with 100ml
of 10% glucose according to the protocol of the
associated assays. When specified, animals received
intraperitoneal injections of 100ml of CQ (10mgml
 1)
1h before coDbait. Tumor size was assessed by caliper
measurements every 3 days, and size was calculated using
the formula (1
2 length width
2). Mice were weighed and
pictures of tumors were taken every week during 100
days. For ethical reasons, the animals were killed when
their tumors reached 2000mm
3. The endpoint used in
survival analysis was death day. For diffusion analyses,
tumors were excised 5h after one session of treatment and
cryosections were labeled with To-Pro5 iodine (Invitrogen,
Cergy, France) and scanned using an Odyssey scanner
(ScienceTec, les Ulis, France). The Local Committee
on Ethics of Animal Experimentation (Orsay, France)
approved all experiments.
Statistical analysis
Descriptive analyses of the tumor responses were
performed for each treatment and each tumor type.
Day 1 was the day of the first treatment session. All
animals were followed for at least 100 days. Median
lifetime was estimated according to the Kaplan–Meier
method. Tumor growth delay was calculated by subtract-
ing the mean tumor volume quadrupling time of the
control group from tumor volume quadrupling times of
individual mice in each treated group. The mean tumor
growth delay was calculated for each treated group, using
individual measurements. We performed a Mann–
Whitney U-test to assess the in vivo effect of the various
treatments on the growth of xenografted tumors using
statEL software (ad Science, Paris, France). The number
of animals (N) and the P-value are reported in Table 2.
All tests were considered significant at the P¼0.05
significance level.
Results
Characterization of Dbait nanoparticles
Cholesterol-conjugated small interfering RNAs have
markedly improved pharmacological properties in vitro
and in vivo.
5 Cholesterol has been shown to increase
dendriplex uptake.
6,7 As cholesterol travels in the blood as
low density lipoproteins and is taken up via receptor-
mediated endocytosis by cells, we questioned if this
property could be utilized for Dbait uptake. We therefore
synthesized a modified Dbait molecule covalently linked
to a fatty chain of cholesterol at the 50-end nearby
hexaethylene-glycol loop (called coDbait). The coDbait
nanoparticle solution was very stable and did not form
aggregates at concentrations as high as 80mgml
 1.
We compared the activity of coDbait to several PEI
particle polyplexes formed with Dbait. PEI has been used
for gene delivery with increasing popularity since its
description as a transfection agent.
8 PEI forms non-
covalent interpolyelectrolyte complexes with DNA,
8
oligonucleotides
9 and RNA.
10 Long PEI chains are more
effective, but more cytotoxic in gene transfection.
11 For
each PEI vector tested, our main goal was to develop a
formulation with the most homogeneous particle size
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Cancer Gene Therapydistribution at the highest Dbait concentration. The
diameter and surface charge of the Dbait/PEI nanopar-
ticles were measured by dynamic laser light scattering.
Using multimodal analysis, we found that branched PEI
(bPEI25K) with a mean size of 25KDa, and linear PEI
with 22KDa (PEI22K) or 11KDa (PEI11K) in size,
formed Dbait complexes with similar properties (Supple-
mentary Table S1). Different ratios of PEI on Dbait were
tested. The lowest ratio resulting in formation of 100%
complexed particles with Dbait was determined by gel
shift assay (data not shown). The ratios of PEI/Dbait
(N/P) 6, 6 and 9 were chosen for PEI11K, PEI22K and
bPEI25K, respectively, for further study. Dbait-PEI
complex particles were stable over a period of 1h in
10% sucrose (data not shown). The highly homogenous
morphology of the spherical particles in the population
(sizes range from 125 to 140nm) was confirmed by
transmission electron microscopy (Figure 1a). Homo-
geneous complex solutions were obtained at concentra-
tions not exceeding 60mgml
 1. The presence of salt in the
dilution buffer at a concentration exceeding 0.8mgml
 1
or prolonged storage, induced aggregation of PEI
complexes. Superfect complexes (60mg Superfect per mg
Dbait) that yielded larger and polydisperse aggregates
(42mm) were used as positive controls. The uncharged
amphiphilic copolymer Lutrol
12 did not form stable
interacting complexes with Dbait and was used as
negative control in some experiments.
Cell uptake of Dbait nanoparticles
We monitored the cellular uptake of the different
nanoparticles using a fluorescent cy3-modified Dbait or
coDbait. The initial fluorescence of the cy3-Dbait
complex was measured immediately before transfection.
In PEI complexes, the Dbait fluorescence was two to
three-fold lower, indicating that the compaction of the
molecules with PEI might quench fluorescence (Table 1).
The coDbait was also less fluorescent than the naked
Dbait, indicating that cholesterol might interact with the
cyanine on the same molecule. Superfect or Lutrol did not
affect fluorescence. Cellular content of human transfected
fibroblast cells was measured by flow cytometry analysis.
The distribution of fluorescence in cells treated with
naked Dbait or Dbait–Lutrol mixture was not different to
the untreated control (data not shown), indicating that
the Dbait molecules did not spontaneously enter into the
cells. Electroporation was relatively inefficient and
increasing the concentration of Dbait did not improve
the transfection efficiency (Figure 1b). All polycationic
polymers (PEI and Superfect) promoted efficient cellular
uptake; however, linear PEIs showed a wider distribution
than Dbait/Superfect or Dbait/PEIb25K complexes
(Figure 1b). Interestingly, coDbait entered cells without
the help of any transfection factors, indicating that
conjugation to cholesterol facilitated DNA uptake as
previously observed for small interfering RNA uptake.
However, the mean fluorescence intensity in cells was
lower than for Dbait/PEI, and a ten-fold higher
concentration of coDbait was required to reach Dbait/
PEI transfection efficiency (Figure 1c and Table 1).
One limitation of the activity of transferred DNA is
its retention in endosomes, which prevents it from
interacting with its target or being transcribed. Inside
the cell, to avoid degradation, DNA must escape from
normal endosomal pathways. Therefore, the efficiency of
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Figure 1 Cellular uptake of formulated Dbait. (a) Microscopic
analyses of Dbait complexes with polyethylenimine (PEI)11k. (b and
c) Flow cytometric analyses of cellular uptake were performed 5h
after beginning treatment for various transfection conditions.
(b) 1.6mgml
 1 Dbait-cy3 (red), Dbait-cy3 with Superfect (black),
bPEI25K (purple), PEI11K (green), PEI22K (blue), electroporation
(light blue); (c) Dbait-cy3 with Superfect (black), 1.6mgml
 1 coDbait-
cy3 (grey), with and without chloroquine (CQ) treatment (light grey)
before transfection, 21mgml
 1 coDbait-cy3 without CQ (brown) and
with CQ (green).
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Cancer Gene TherapyDNA delivery is associated not only with cellular uptake,
but also with destabilization and escape from endo-
somes.
13 PEI is known to have a high buffering capacity
that facilitates DNA release from endosomes and lyso-
somes (proton sponge hypothesis).
8 Recycling cholesterol
from endosomes requires systems that are poorly under-
stood. Fusogenic agents such as CQ raise endosomal pH
and inhibit sequestration of DNA in endosomes. We
tested the capacity of CQ to enhance coDbait uptake by
adding 50mM to the cells 30min before transfection. CQ
increased the mean fluorescence of cells treated with cy3–
coDbait by two- to four-fold (Figure 1c).
Binding of DNA-PK catalytic subunits (DNA-PKcs)
kinase to Dbait molecules
3 triggers its activation, which is
an indicator of the amount of Dbait released in the cell.
3
Addition of cholesterol did not affect the ability of Dbait
to activate purified DNA-PKcs (Figure 2a). We have
previously shown that the DNA-PKcs kinase activation
by Dbait can be monitored by the amount of H2AX
phosphorylation in the cell.
3 Both Dbait/PEI and coDbait
induced H2AX phosphorylation in treated cells
(Figure 2b). Branched and linear PEI/Dbait complexes
rapidly promoted H2AX phosphorylation (Figure 2c)
that reached a maximal value 1h after the end of
transfection and persisted for 24h. Dbait-induced kinase
activity was very low after electroporation at any time-
point (Figure 2c). Transfection with ten-fold more
coDbait was very inefficient and required at least 24h
to reach a maximal value of phosphorylated H2AX.
Addition of CQ during transfection increased the level of
activation of DNA-PKcs in coDbait-transfected cells to
that observed with ten-fold less Dbait/PEI at 24h after
transfection (Figure 2c). CQ did not increase DNA-PKcs
activation in Dbait/PEI-transfected cells, indicating that
Dbait is efficiently released from endosomes when
complexed to PEI.
14 As cellular uptake of coDbait was
not increased 24h after transfection, the slow activation
of DNA-PKcs indicates the slow release of coDbait from
endosomes.
Cellular uptake and overall toxicity in zebrafish early
embryos
Zebrafish (Danio rerio) have recently emerged as a
valuable model organism in the drug discovery processes,
including target identification, disease modeling, lead
discovery and compound toxicology. Their evolutionary
proximity to humans, embryonic accessibility and high
fecundity make zebrafish favorable for screening large
numbers of small molecules in vivo.
15 Analysis of Dbait
uptake and its activity on cell cultures does not allow us to
conclude on Dbait diffusion, cellular uptake and activity
in the whole organism. To assess these activities, we
injected Dbait-cy3 nanoparticles, into the intercellular
space of 1000 cell stage (stage 1K) zebrafish embryos.
16
This protocol enabled in vivo observation by confocal
microscopy of real-time Dbait-cy3 distribution at the
cellular and subcellular level, as well as its activity on the
rapidly-dividing cells of the early zebrafish embryo
(Figure 3a). As shown in Figure 3b, naked Dbait-cy3
injected at the animal pole of stage 1K embryos, rapidly
diffused throughout the whole blastoderm and was no
longer detected 15min after injection. The addition of
Lutrol enabled the retention of Dbait in the extracellular
space around the injection point, but did not facilitate
cellular uptake (Figure 3c). In the presence of Superfect
or PEI, numerous fluorescent patches were observed
inside the cells, indicating efficient cellular uptake
(Figures 3d–f). The coDbait-cy3 demonstrated different
behavior with strong and persistent staining of plasma
membranes, together with patchy intracellular fluores-
cence (Figure 3g). Note that coDbait localization at
the cellular membrane was also partially observed in
Table 1 Fluorescence and cellular uptake of formulated Dbait
Molecules/method Dbait Chloroquine Fluorescence
a MCC Cor MCC MCC Cor MCC
(mgml
 1) (100mgml
 1)  10
6mg
 1ml
 1 5h 5h 24h 24h
——   0 3 ND 3 ND
—— + 0 3 N D N D N D
Electroporation 1.6   6.17 9 1 11 2
Dbait 1.6   6 3 0.4 3 0.5
Dbait/PEI11K 1.6   1.92 26 14 13 7
Dbait/bPEI25K 1.6   3.04 52 17 58 19
Dbait/PEI22K 1.6   3.32 54 16 43 13
Dbait/Superfect 1.6   6.41 220 34 204 32
Dbait/Superfect 1.6 + 6.41 218 34 ND ND
coDbait 1.6   3.47 10 3 ND ND
coDbait 1.6 + 3.47 21 6 ND ND
coDbait 16   3.47 66 19 64 18
coDbait 16 + 3.47 236 68 214 62
coDbait 32   3.47 145 42 ND ND
coDbait 32 + 3.47 390 112 ND ND
Abbreviations: Cor MCC, corrected cellular content FL2/fluorescence; MCC, mean cellular content FL2 value (43 experiments);
ND, not defined.
aFluorescence at FL2 value.
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Cancer Gene Therapymammalian cells (Supplementary Figure S1). Incubation
of embryos with CQ before injection converted part of
the large fluorescent patches of coDbait into a diffuse
intracellular distribution (Figure 3h).
The observation of phenotypic effects 24h after
injection enabled the assessment of Dbait activity and
the overall toxicity of the treatment. Dbait fluorescence
was mainly detected in the head cells of larvae, 24h after
injection (Figures 4a–c), which according to the zebrafish
fate map development,
17 are derived from the animal pole
area of pre-gastrulation embryos that received the Dbait
injection. Injection of Dbait without adjuvant or com-
bined with Lutrol (Lu) showed no effect on development
(Figure 4d) correlating with the poor intracellular uptake
of Dbait described above. Addition of adjuvant led to cell
death in the head and, correlating with the injected
volume, extensive cell death and teratogenesis might
be observed. The 24h phenotypes were categorized as
described in Figure 4, allowing quantification of the
toxicity of the injected mixture. For the same concentra-
tion of Dbait, clear differences appeared in terms of cell
death and subsequent developmental abnormalities,
depending on the adjuvant. Addition of Superfect (sup)
was very toxic to embryonic cells and extensive cell death
at early stages resulted in a high percentage of type 2
phenotypes. Addition of PEI (25, 22 and 11K) proved to
be also toxic to zebrafish blastomeres. Although less toxic
than Dbait/PEI, coDbait injection resulted in significant
cell death. Pre-incubation of embryos with CQ did not
significantly increase toxicity. Altogether, early embry-
onic cell death and subsequent developmental abnormal-
ities was a fast and reliable protocol for assessing the
overall toxicity of Dbait±adjuvant in zebrafish embryos.
Correlation of cell death with cellular uptake suggested
that the anti-tumoral activity of Dbait in embryonic cells
might have an important role in toxicity. Indeed, embryo
cells, after injection of Dbait directly into cytoplasm,
rapidly encounter mitotic catastrophe as a consequence
of Dbait activity on rapidly proliferating cells (unpub-
lished data).
We confirmed that toxicity of nanoparticules with
Superfect or PEI was partly due to the Dbait activity
using nanoparticules formed with inactive siDNA mole-
cules: 8H, a short 8-bp long double-stranded molecule
and, 64ss, a single-stranded molecule corresponding to a
32-bp long Dbait with non-complementary strands. None
of these molecules bind or activate DNA-PKcs.
3 The
toxicity of the nanoparticules with inactive siDNA was
significantly lower than toxicity of nanoparticles formed
with Dbait (Figure 4e).
Dbait/PEI11K coDbait+CQ Dbait
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Figure 2 Activity of formulated Dbait. (a) DNA-dependent protein kinase (DNA-PK) activation was measured after addition of 50mg purified
enzyme complex to no DNA, 0.25mg Dbait or 0.25mg coDbait. (b) Immunodetection of g-H2AX in cells 24h after treatment (down panels) with
1.6mgml
 1 Dbait, 1.6mgml
 1 Dbait/polyethylenimine (PEI)11K, 16mgml
 1 coDbait with CQ and corresponding cell nuclei stained with 4’,6-
diamidino-2-phenylindole (DAPI; upper panels). Scale bar: 20mm. (c) Quantification of g-H2AX, 1h (black) and 24h (grey) after treatment with
various Dbait formulations. All transfections were performed with 1.6mgml
 1 Dbait or 16mgml
 1 coDbait. When indicated, CQ was added before
transfection.
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Cancer Gene TherapyLocal and systemic toxicity in mice
To assess the relevance of toxicity data on zebrafish
embryo with toxicity in mammalian, we analyzed the
tolerance of nude mice skin to repeated administration
of Dbait/PEI1K, Dbait/PEI22K, Dbait/bPEI25K and
coDbait. The toxicity of the different formulated Dbait
was analyzed after three daily subcutaneous (SC) injec-
tions. All the Dbait/PEI showed high toxicity with
injections that were tolerated at 3.75mgkg
 1 (3.75nmoles
per injection), but at 5mgkg
 1, it started to trigger local
inflammation associated with local necrosis that rapidly
disappeared with the arrest of the treatment. Intravenous
(IV) injection toxicity gave similar results; the Dbait/PEI
IV injections were lethal at 3mgkg
 1 (3nmoles per
injection), with death occurring during injection, probably
by blood vessel clogging. Slow injections by perfusion
(0.4mlmin
 1) increased tolerance up to 6mgkg
 1 Dbait/
PEI (6nmoles per injection), confirming that most of the
IV toxicity is due to the local concentration at the bolus
injection site. The coDbait, with or without CQ, did not
show any toxicity at all doses tested (up to 640mgkg
 1;
800nmoles per injection), irrespective of the route chosen:
SC, IV bolus or IV perfusion.
Antitumoral activity in xenografted tumors
The antitumoral effect of the various Dbait formulations
was tested, at doses that do not show any toxicity on
healthy tissues, in combination with radiotherapy on
SK28-xenografted human melanoma. Dbait/vector com-
plexes were administered 5h before each irradiation,
using intratumoral (IT) injections. The results were
consistent with the observations from previous experi-
ments. The Dbait/PEI formulations induced tumor
growth delay and tumor regression after IT injection
(Table 2 and Figure 5a). The Dbait/PEI22k formulation
was the most efficient. Nanoparticules formed with the
Figure 3 Dbait injection into stage 1K zebrafish embryos. (a–h) 2–5nl Dbait-cy3 were injected either alone (b) or with adjuvant (c–h) indicated
bottom left into the extracellular space at the animal pole of act26:egfp-ras zebrafish embryos at cell stage 1K. (a) Bright field and epifluoresence
overlay of an injected embryo at sphere stage (1h after injection), lateral view, scale bar 250 microns, white box is a 3  magnification in right
panel, white arrowhead indicates the animal pole. (b–h) Injected embryos imaged live by confocal microscopy (Leica SP2 488 and 561nm
simultaneous excitation) from the animal pole 15–30min after injection. Left panel, white box is a 3  magnification in right panel (scale bar
100mm). White arrows point to intracellular Dbait-cy3, white arrowheads point to Dbait-cy3 staining either at the cell surface (b, f, g, h) or in the
extracellular space (c).
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Cancer Gene Therapyinactive 8H molecule and PEI11K did not show
significant effect on tumor growth, indicating that the
tumor regression observed with Dbait/PEI11K is mainly
due to Dbait activity (Figure 5c). The coDbait adminis-
tration without CQ did not remarkably improve radio-
therapy efficiency. Although radiosensitization effects
have been observed with administration of a high CQ
concentration,
18 prophylactic doses of CQ (intraperito-
neal injections of 100mg) did not affect tumor growth in
control groups, nor in groups receiving radiotherapy. In
contrast, the radiosensitivity of tumors significantly
increased when mice received CQ followed by coDbait
1h later (Table 2 and Figure 5b). The activity of Dbait
and coDbait in tumoral cells was confirmed by the
activation of DNA-PKcs demonstrated by H2AX phos-
phorylation (Figure 6b). Activation of DNA-PKcs in a
large number of cells within the tumor area correlated
with the accumulation of small cells, with fragmented
nuclei typical of apoptotic cells (Figure 6b). This result
confirmed the previous observation that activation of
DNA-PKcs by Dbait induced cell death in tumor cells.
2,3
Although drug administration by IT injection has been
used in many trials, it is currently advised to avoid this
route of delivery in clinical assays. We investigated
how Dbait/PEI11K or coDbait could be administered
SC in the area adjacent to the tumor. This route of
administration has been successfully used in several
clinical assays.
19–21 We first compared the diffusion of
the molecules in tumors treated by one IT injection or two
SC injections performed at opposite sides of the tumor
(Figure 6a). Fluorescent Dbait complexed to PEI11k
tended to form aggregates at the site of injection and
diffused progressively to the edge of the tumor. In
contrast, coDbait showed a more even distribution
around the injection site, whether inside the tumor or in
its vicinity. Despite demonstrating a reduced diffusion to
the tumor, SC injections of Dbait/PEI11K or coDbait
increased tumor growth control by irradiation (Table 2
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Figure 4 Phenotypes 24h after Dbait injection into the extracellular space of cell stage 1K zebrafish embryos. (a–c) Lateral views anterior to
the left of zebrafish embryos, 24h after Dbait-cy3þpolyethylenimine (PEI) injection (2–5nl) at the animal pole of cell stage 1K zebrafish
embryos: top panel, bright field view; bottom panel, 2  magnification of the head region with epifluorescence overlay showing in red Dbait-cy3,
scale bar 250mm. (a) Type 1 phenotype indistinguishable from non-injected (not shown). (b) Type 2 mild phenotype with extensive cell death in
the head region. (c) Type 3 strong teratogenesis and widespread cell death. (d) Histogram showing the percentage of the three phenotypic
classes depending on the adjuvant. More than 100 embryos were analyzed for each condition. Sup: Superfect; 25, 22, 11K PEI of the
corresponding size; Lu, Lutrol; CQ, chloroquine; ‘ ’, without adjuvant. (e) Histogram showing the percentage of the animals with type 1
phenotype after injections of nanoparticules formed with 8H, 64ss or Dbait32H and Superfect or PEI11K. The Dbait32H, and the 8H and 64ss
inactive nanoparticules, were used at equivalent adjuvant concentrations.
Distribution and antitumoral activity of Dbait
N Berthault et al
702
Cancer Gene Therapyand Figure 5). Increasing the number of injection sites
should allow a significant improvement to tumor growth
control without the addition of local toxicity.
Discussion
In this work, we used a set of assays to guide development
of administration protocols and drug formulation. These
assays enabled the comparison of different formulations
of Dbait before performing preclinical assays on mice.
Cellular and zebrafish embryo assays were used to assess
the efficiency of Dbait cellular uptake, a prerequisite step
in the antitumoral drug effect, and for selection of the
most appropriate protocols and formulations for pre-
clinical studies on mammals.
Zebrafish embryo possesses a cell-autonomous mecha-
nism that can trigger apoptosis in response to DNA
damage.
22,23 We have exposed early zebrafish embryos to
different Dbait containing nanoparticles that are pre-
dicted to specifically inhibit DNA repair. Overall, toxicity
in the zebrafish embryo did not correlate with toxicity in
mice skin or after systemic injection, but corresponded to
cellular Dbait activity. Dbait/PEI (5mM) and coDbait
Table 2 Xenografted mice survival after irradiation associated with various treatments
Dbait/vector
complexes
Dbait conc. Mode
admin.
N
mice
Median
survival time
Mean
TGD
a
s.d.
TGD
Mean %
TGD
TGD
P-value
b
Mock — IT 56 74 8 12 139 —
Dbait 6 60mg (3nmol) IT 6 70 2 8 108 0.18
Dbait/PEI11K 6 60mg (3nmol) IT 38 4100 436 19 4281 1.06 10
 10
Dbait/PEI22K 6 60mg (3nmol) IT 10 4100 448 28 4341 2.73 10
 4
Dbait/PEIb25K 6 60mg (3nmol) IT 19 4100 451 21 4356 1.31 10
 8
Dbait/Lutrol 6 60mg (3nmol) IT 10 74 4 5 121 0.57
Dbait/PEI11K SC 6 150mg (7.5nmol) SC 12 4100 426 22 4229 1.52 10
 3
CQ — IT 6 68 7 6 134 0.93
coDbait 6 600mg (30nmol) IT 11 67 19 25 195 0.17
coDbait+CQ 6 600mg (30nmol) IT 13 98 444 26 4321 8.66 10
 6
coDbait+CQ SC 6 1.2mg (60nmol) SC 16 92 424 26 4224 1.45 10
 2
Abbreviations: CQ, chloroquine; IT, intratumoral injection; Mode admin, mode of administration; SC, subcutaneous injection;
TGD, tumor growth delay;
aTGD was calculated as described in Material and Methods.
bStatistical analyses were performed using mock treatment as a reference.
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Figure 5 Kaplan–Meier survival representation of animals with SK28 tumors treated in six sessions over 2 weeks with different nanoparticules
associated with radiotherapy (5Gy per session). The dose of nanoparticules per session was 60mg (3nmol) for Dbait/adjuvant nanoparticules by
intratumoral (IT) injections, 150mg (7.5nmol) for Dbait/polyethylenimine (PEI)11K subcutaneous (SC) injections, 600mg (30nmol) for coDbait IT
injections and 1.2mg (60nmol) by coDbait SC injections. (a) Comparison of treatment efficiencies with radiotherapy associated with different
nanoparticules: IT injections of 5% glucose vehicle (Mock), Dbait without adjuvant (Dbait), Dbait/PEI11K, Dbait/PEI22K, Dbait/PEI25K, Dbait/
Lutrol, or SC injections of Dbait/PEI11K (Dbait/PEI11K SC). NT, non-irradiated and non-treated control. (b) Comparison of coDbait treatments
and radiotherapy with (þ CQ) or without intraperitoneal injections of chloroquine. coDbait þCQ or coDbait, IT injections of coDbait; coDbait
þCQ SC, SC injections of coDbait. Control cells treated by radiotherapy with CQ (CQ) showed similar survival than control receiving only
radiotherapy (Mock in a). (c) Comparaison of survival of animals treated by radiotherapy and IT injections of nanoparticules formed with PEI11K
and Dbait (Dbait/11K) or 8H (8H/PEI11K) molecules. Mock, irradiated tumors injected with 5% glucose vehicle.
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Cancer Gene Therapy(50mM)þCQ that triggered comparable DNA-PKcs
activation in cell culture had similar toxic effects on
zebrafish embryos (Figure 4d) and displayed significant
antitumoral activity on mouse tumors (Table 2). How-
ever, although coDbait is very well tolerated by healthy
tissue, Dbait/PEI proved to be highly toxic. These results
Dbait/PEI
NT
coDbait
dapi γ-H2AX
Dbait/PEI
coDbait
Figure 6 Diffusion and activity in tumors. Tumors were injected with 1.6mg Dbait-cy5.5/polyethylenimine (PEI) or 16mg coDbait-cy5.5, excised
and analyzed the following day for fluorescence distribution and DNA-PKcs activation. (a) Diffusion of fluorescent Dbait after two types of
injections, intratumoral (IT) injection (A and B), or subcutaneous (SC) injections (C and D); white arrows indicate the sites of injection; scale:
2mm. (b) DNA-PKcs activity was detected by H2AX phosphorylation (g-H2AX) in tumors without treatment (NT) or after IT injection of Dbait/PEI
or coDbait; left panels, cell nuclei stained with 4’,6-diamidino-2-phenylindole (DAPI); right panels, immunodetection of g-H2AX; scale, 20mm.
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Cancer Gene Therapysuggest that toxicity in zebrafish early embryos is an
indicator of tumor sensitivity rather than healthy tissue
sensitivity. These observations are consistent with the
sensitivity to antitumoral activity of zebrafish embryonic
cells that share characteristic properties with tumor
cells, including mitotic index and, biochemical and
phenotypic traits.
15,24 Consistent with this hypothesis,
we recently developed a method for measuring embryo
cell proliferation
25 and observed Dbait anti-proliferation
activity by direct intracellular injection of Dbait into
zebrafish blastomeres (unpublished data).
PEI polymers were the most efficient, of all adjuvant
molecules tested, in forming Dbait complexes. Their use
was limited, however, by their toxicity on tissues, as well
as in the blood system. Local toxicity was partly
overcome by slow administration (perfusion) and by
administering the doses into different injection sites. The
covalent combination of cholesterol and Dbait provided
the most promising alternative for Dbait delivery to the
cells. Indeed, the lack of toxicity within the range of tested
doses suggests that this molecule might prove useful
despite the high doses required for antitumoral effects.
The doses of 3 and 30nmoles per injection of Dbait/
PEI11K and coDbait, respectively, tripled the delay in
tumor growth delay induced by irradiation alone. The
respective toxicity of both nanoparticles (LD50 of
3.7nmoles for Dbait/PEI and 4800nM for coDbait in
mice) resulted in relative ratios of efficiency dose/toxicity
dose of 0.8 for Dbait/PEI11K and o0.037 for coDbait,
indicating that coDbait is safer and is a good candidate
for local administration in clinical trials.
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